Shire withdraws EU filing of Daytrana for ADHD with no plans to resubmit
This article was originally published in Scrip
Shire has withdrawn its EU marketing application for its ADHDtransdermal patch product, Daytrana (methylphenidate transdermal system) for use in children, licensed from Noven. There are no plans to resubmit the filing.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.